GSK says antibody drug extended lives of those with blood cancer

GSK said its antibody drug Blenrep, which had its US clearance revoked last year, helped patients live longer without their blood cancer worsening in a late-stage study. Volunteers taking the medicine with two other older ones fared better than a control group taking a standard regimen for a form of myeloma that returned after initial treatment, GSK said in a statement. Blenrep is part of GSK’s push in cancer treatments but it suffered a setback last year when US regulators withdrew its clearance after a clinical trial failure.